Internal Medicine, Hematology & Oncology · Lake Worth, FL
NPI
1376742833
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3450 Lantana Rd, Ste100
Lake Worth, FL, 33462
Phone (561) 965-1864
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
119,026 services
Medicare patients, 2024
339
Average age 77
Drug cost, 2024
$5.9M
1,582 prescriptions
Company payments, 2025
$5,533
From 48 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jose A Ortega III was code J1439 (injection, ferric carboxymaltose, 1 mg), 40,500 times for 27 patients. In total Jose A Ortega III billed 119,026 services in 120 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-01-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 40,500 | 27 | $0.87 | $35K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 13,050 | 14 | $2.31 | $30K |
| J0897 Injection, denosumab, 1 mg | Office | 2,460 | 11 | $20.71 | $51K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 988 | 13 | $0.09 | $88.64 |
| 85025 Blood Count | Office | 804 | 199 | $7.50 | $6,031 |
| 36415 Venipuncture Blood Collection | Office | 702 | 192 | $8.55 | $6,005 |
| 80053 Clinical Chemistry | Office | 562 | 191 | $10.35 | $5,817 |
| 99214 Office E&M - Established | Office | 397 | 166 | $100.11 | $40K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 380 | 62 | $0.52 | $197 |
| 82728 Clinical Chemistry | Office | 255 | 113 | $13.36 | $3,407 |
| 83540 Clinical Chemistry | Office | 254 | 113 | $6.34 | $1,610 |
| 84466 Clinical Chemistry | Office | 254 | 113 | $12.50 | $3,175 |
| 96372 Injection Administration | Office | 203 | 33 | $10.96 | $2,225 |
| 83615 Clinical Chemistry | Office | 200 | 98 | $5.92 | $1,184 |
| 96367 Intravenous Infusion, Hydration | Office | 179 | 21 | $22.53 | $4,033 |
By year: 2022 $1.2M for 98,449 services; 2023 $1.1M for 96,434 services; 2024 $1.5M for 119,026 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 804 | 199 | $7.50 | $6,031 |
| 36415 Venipuncture Blood Collection | 702 | 192 | $8.55 | $6,005 |
| 80053 Clinical Chemistry | 562 | 191 | $10.35 | $5,817 |
| 82728 Clinical Chemistry | 255 | 113 | $13.36 | $3,407 |
| 83540 Clinical Chemistry | 254 | 113 | $6.34 | $1,610 |
| 84466 Clinical Chemistry | 254 | 113 | $12.50 | $3,175 |
| 83615 Clinical Chemistry | 200 | 98 | $5.92 | $1,184 |
| 82607 Clinical Chemistry | 65 | 54 | $14.78 | $961 |
| 82378 Clinical Chemistry | 57 | 20 | $18.58 | $1,059 |
| 82746 Clinical Chemistry | 46 | 43 | $14.41 | $663 |
Medicare prescription drug claims, 2024
In 2024, the drug Jose A Ortega III prescribed most often to Medicare patients was Eliquis (Apixaban), with 128 prescriptions and refills. In total Jose A Ortega III wrote 1,582 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 128 | 152 | 26 | $89K |
| Anastrozole Generic | 80 | 151 | 22 | $883 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 75 | 75 | 23 | $4,112 |
| Letrozole Generic | 65 | 133 | 17 | $786 |
| Hydroxyurea Generic | 57 | 105 | 14 | $1,642 |
| Oxycodone Hcl Generic | 55 | 55 | Under 11 | $628 |
| Imbruvica Ibrutinib | 49 | 49 | Under 11 | $798K |
| Brukinsa Zanubrutinib | 41 | 41 | Under 11 | $507K |
| Prednisone Generic | 40 | 40 | Under 11 | $171 |
| Xtandi Enzalutamide | 40 | 40 | Under 11 | $552K |
| Dexamethasone Generic | 39 | 42 | 12 | $642 |
| Ondansetron Odt Ondansetron | 38 | 40 | 23 | $890 |
| Acyclovir Generic | 36 | 55 | 11 | $362 |
| Pomalyst Pomalidomide | 35 | 35 | Under 11 | $816K |
| Exemestane Generic | 34 | 52 | Under 11 | $3,831 |
Brand drugs: 548 claims; generic drugs: 1,034 claims; opioid claims: 216.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jose A Ortega III $5,533 ($5,533 in general payments such as food, travel and fees) from 48 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,234.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 23 | $1,234 |
| AstraZeneca Pharmaceuticals LP AZN | 20 | $442 |
| Pfizer Inc. PFE | 16 | $273 |
| Janssen Biotech, Inc. JNJ | 12 | $272 |
| Genzyme Corporation SNY | 6 | $271 |
| Celgene Corporation BMY | 12 | $184 |
| Abbvie Inc. ABBV | 9 | $180 |
| Tempus AI, Inc TEM | 4 | $167 |
| Caris MPI, Inc. | 7 | $162 |
| Novocure Inc. NVCR | 1 | $152 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.